What is the initial treatment for systemic lupus erythematosus?

Initial Treatment for Systemic Lupus Erythematosus

All patients with SLE should immediately start hydroxychloroquine (≤5 mg/kg/day real body weight) combined with glucocorticoids tailored to disease severity, with prompt addition of immunosuppressive agents in moderate-to-severe disease to enable rapid steroid tapering. 1

Core Treatment Framework

Universal First-Line Therapy

Hydroxychloroquine is mandatory for all SLE patients unless contraindicated (Level 1b/A evidence). 1 This provides:

• Reduced mortality
• Prevention of disease flares
• Protection against thrombosis and infections
• Improved long-term outcomes

The dose must not exceed 5 mg/kg of actual body weight to minimize retinal toxicity risk. 1

Glucocorticoid Strategy

The glucocorticoid approach depends on disease severity:

For moderate-to-severe disease:

• Start with IV methylprednisolone pulses (250-1000 mg/day for 1-3 days) 1
• This enables use of lower starting oral doses
• Begin oral prednisone at 0.3-0.5 mg/kg/day (not the traditional higher doses) 2
• Target: taper to ≤7.5 mg/day by 3-6 months, ideally ≤5 mg/day for maintenance 1, 3

For mild disease:

• Lower-dose oral glucocorticoids may suffice initially
• Still aim for rapid taper with immunosuppressive support

Critical Pitfall to Avoid

Do not use glucocorticoids as monotherapy beyond initial control. Chronic glucocorticoid use (even at "low" doses >7.5 mg/day) causes irreversible organ damage, infections, osteonecrosis, and increased mortality. 1, 3 The evidence now strongly supports that doses >5 mg/day maintenance are associated with worse outcomes.

Immunosuppressive Agent Selection

Non-Organ-Threatening Disease

If patients cannot taper glucocorticoids below 7.5 mg/day or have inadequate response to hydroxychloroquine plus glucocorticoids, add:

• Methotrexate (Level 1b/B evidence) 1
• Azathioprine (Level 2b/C) 1
• Mycophenolate (Level 2a/B) 1

These agents should be initiated early (within weeks, not months) to expedite glucocorticoid discontinuation. 1

Organ-Threatening Disease

For severe manifestations (lupus nephritis, neuropsychiatric disease, severe cytopenias), immunosuppressive agents must be included in initial therapy, not added later: 1

Lupus Nephritis (Class III/IV):

• Mycophenolate mofetil 2-3 g/day (Level 1a/A) OR 1
• Low-dose IV cyclophosphamide (500-750 mg/m² monthly × 6 months) (Level 2a/B) 1
• Both have equivalent efficacy with different toxicity profiles
• For high-risk patients (reduced GFR, crescents, necrosis), high-dose cyclophosphamide can be considered 1

Severe Hematologic/Neuropsychiatric Disease:

• High-dose glucocorticoids (including IV pulses) 1
• Cyclophosphamide for life-threatening manifestations 1
• Mycophenolate or azathioprine for maintenance 1

Treatment Goals

Aim for remission or low disease activity (SLEDAI ≤4, physician global assessment ≤1, prednisone ≤7.5 mg/day on well-tolerated immunosuppressives). 1 This approach halts damage accrual and prevents flares better than accepting higher disease activity.

For lupus nephritis specifically: target at least 50% proteinuria reduction by 6 months and complete renal response (proteinuria <0.5-0.7 g/24h) by 12 months. 2

Adjunctive Measures (Start Immediately)

• Ophthalmologic screening at baseline for hydroxychloroquine 1
• Cardiovascular risk modification (consider low-dose aspirin, statins based on risk profile) 1
• Bone protection (calcium, vitamin D, bisphosphonates if indicated) 4
• UV photoprotection 4
• Vaccination (pneumococcal, influenza, herpes zoster with recombinant vaccine) 3

Key Algorithmic Decision Points

1. Is disease organ-threatening?

   • YES → Hydroxychloroquine + IV methylprednisolone pulses + immunosuppressive agent (mycophenolate or cyclophosphamide) immediately
   • NO → Hydroxychloroquine + oral glucocorticoids, add immunosuppressive within 4-8 weeks if steroids cannot taper

2. Can glucocorticoids taper to ≤7.5 mg/day by 3 months?

   • NO → Add/escalate immunosuppressive therapy immediately
   • YES → Continue taper to ≤5 mg/day, consider withdrawal if sustained remission

3. Is this lupus nephritis?

   • YES → Kidney biopsy essential; start mycophenolate or cyclophosphamide based on class and risk factors 1
   • NO → Proceed with non-renal algorithm

The evidence strongly contradicts older approaches of prolonged high-dose glucocorticoid monotherapy or delayed immunosuppressive introduction. Modern SLE management requires aggressive early combination therapy to achieve rapid disease control while minimizing glucocorticoid exposure. 1, 2, 3